Trade Medivir B - MEDIVIR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.14 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.021941% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000281% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | SEK | ||||||||
Margin | 5% | ||||||||
Stock exchange | Sweden | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Medivir AB ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Prev. Close* | 2.68 |
Open* | 2.66 |
1-Year Change* | -66.92% |
Day's Range* | 2.62 - 2.66 |
52 wk Range | 2.45-8.07 |
Average Volume (10 days) | 875.92K |
Average Volume (3 months) | 6.22M |
Market Cap | 337.28M |
P/E Ratio | -100.00K |
Shares Outstanding | 67.10M |
Revenue | 5.71M |
EPS | -1.11 |
Dividend (Yield %) | N/A |
Beta | 0.21 |
Next Earnings Date | Feb 15, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2024 | 2.68 | -0.04 | -1.47% | 2.72 | 2.72 | 2.68 |
Mar 26, 2024 | 2.76 | 0.08 | 2.99% | 2.68 | 2.78 | 2.68 |
Mar 22, 2024 | 2.72 | 0.00 | 0.00% | 2.72 | 2.74 | 2.70 |
Mar 21, 2024 | 2.72 | -0.02 | -0.73% | 2.74 | 2.74 | 2.70 |
Mar 20, 2024 | 2.78 | 0.02 | 0.72% | 2.76 | 2.78 | 2.74 |
Mar 19, 2024 | 2.76 | -0.06 | -2.13% | 2.82 | 2.82 | 2.76 |
Mar 18, 2024 | 2.82 | 0.00 | 0.00% | 2.82 | 2.82 | 2.80 |
Mar 15, 2024 | 2.66 | -0.04 | -1.48% | 2.70 | 2.72 | 2.66 |
Mar 14, 2024 | 2.70 | 0.02 | 0.75% | 2.68 | 2.70 | 2.68 |
Mar 13, 2024 | 2.70 | 0.00 | 0.00% | 2.70 | 2.70 | 2.70 |
Mar 12, 2024 | 2.66 | -0.04 | -1.48% | 2.70 | 2.70 | 2.66 |
Mar 11, 2024 | 2.70 | 0.00 | 0.00% | 2.70 | 2.70 | 2.66 |
Mar 8, 2024 | 2.66 | -0.16 | -5.67% | 2.82 | 2.82 | 2.66 |
Mar 7, 2024 | 2.78 | 0.04 | 1.46% | 2.74 | 2.84 | 2.74 |
Mar 6, 2024 | 2.82 | -0.14 | -4.73% | 2.96 | 2.96 | 2.82 |
Mar 5, 2024 | 2.92 | 0.00 | 0.00% | 2.92 | 2.94 | 2.88 |
Mar 4, 2024 | 2.92 | 0.00 | 0.00% | 2.92 | 2.92 | 2.92 |
Mar 1, 2024 | 3.02 | -0.06 | -1.95% | 3.08 | 3.08 | 3.00 |
Feb 29, 2024 | 3.04 | -0.04 | -1.30% | 3.08 | 3.10 | 3.04 |
Feb 28, 2024 | 3.10 | -0.04 | -1.27% | 3.14 | 3.14 | 3.08 |
Medivir B Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, April 30, 2024 | ||
Time (UTC) 10:59 | Country SE
| Event Q1 2024 Medivir AB Earnings Release Q1 2024 Medivir AB Earnings ReleaseForecast -Previous - |
Tuesday, May 7, 2024 | ||
Time (UTC) 10:59 | Country SE
| Event Medivir AB Annual Shareholders Meeting Medivir AB Annual Shareholders MeetingForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 4.408 | 25.538 | 13.948 | 8.724 | 23.863 |
Revenue | 4.408 | 25.538 | 13.948 | 8.724 | 23.863 |
Cost of Revenue, Total | 69.078 | 66.421 | 46.45 | 91.063 | 235.129 |
Gross Profit | -64.67 | -40.883 | -32.502 | -82.339 | -211.266 |
Total Operating Expense | 91.762 | 87.656 | 56.848 | 134.703 | 374.893 |
Selling/General/Admin. Expenses, Total | 20.735 | 21.415 | 24.931 | 35.033 | 118.177 |
Research & Development | |||||
Depreciation / Amortization | 2.571 | 2.595 | 4.43 | 7.085 | 24.532 |
Other Operating Expenses, Total | 0.632 | -0.495 | -16.318 | 1.522 | -2.945 |
Operating Income | -87.354 | -62.118 | -42.9 | -125.979 | -351.03 |
Interest Income (Expense), Net Non-Operating | -1.411 | -0.46 | 0.28 | 2.644 | 0.555 |
Net Income Before Taxes | -88.765 | -62.579 | -42.62 | -123.334 | -350.475 |
Net Income After Taxes | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
Net Income Before Extra. Items | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
Total Extraordinary Items | |||||
Net Income | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
Income Available to Common Excl. Extra. Items | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
Income Available to Common Incl. Extra. Items | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
Dilution Adjustment | |||||
Diluted Net Income | -88.765 | -63.125 | -42.62 | -123.44 | -350.314 |
Diluted Weighted Average Shares | 55.736 | 52.815 | 29.5798 | 29.5798 | 29.1755 |
Diluted EPS Excluding Extraordinary Items | -1.5926 | -1.19521 | -1.44085 | -4.17311 | -12.0071 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -1.59323 | -1.20358 | -1.48676 | -4.17311 | -12.0062 |
Unusual Expense (Income) | -0.035 | -0.68 | -1.358 | 0 | 0 |
Total Adjustments to Net Income | |||||
Other, Net | -0.001 | 0.001 | |||
Interest Expense (Income) - Net Operating | -1.219 | -1.6 | -1.287 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 2 | 0.4 | 2.308 | 1.1 | 0.5 |
Revenue | 2 | 0.4 | 2.308 | 1.1 | 0.5 |
Cost of Revenue, Total | 21.2 | 13.1 | 15.778 | 11.1 | 16.4 |
Gross Profit | -19.2 | -12.7 | -13.47 | -10 | -15.9 |
Total Operating Expense | 29 | 20 | 20.962 | 15.7 | 22.6 |
Selling/General/Admin. Expenses, Total | 7.4 | 6.2 | 4.735 | 3.9 | 5.8 |
Depreciation / Amortization | 0.7 | 0.7 | 0.671 | 0.7 | 0.6 |
Other Operating Expenses, Total | -0.3 | 0 | -0.222 | 0 | -0.2 |
Operating Income | -27 | -19.6 | -18.654 | -14.6 | -22.1 |
Interest Income (Expense), Net Non-Operating | 0.4 | 0.7 | 0.489 | -0.2 | -1.1 |
Net Income Before Taxes | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Net Income After Taxes | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Net Income Before Extra. Items | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Net Income | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Income Available to Common Excl. Extra. Items | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Income Available to Common Incl. Extra. Items | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Diluted Net Income | -26.6 | -18.9 | -18.065 | -14.8 | -23.1 |
Diluted Weighted Average Shares | 55.736 | 55.736 | 55.736 | 55.736 | 55 |
Diluted EPS Excluding Extraordinary Items | -0.47725 | -0.3391 | -0.32412 | -0.26554 | -0.42 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
Diluted Normalized EPS | -0.47725 | -0.3391 | -0.32412 | -0.26554 | -0.42 |
Other, Net | 0.1 | 0.1 | |||
Total Adjustments to Net Income |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 123.044 | 225.917 | 78.931 | 152.811 | 311.64 |
Cash and Short Term Investments | 117.434 | 221.167 | 70.007 | 134.509 | 286.281 |
Cash | 6.448 | 14.69 | 14.038 | 34.3 | 47.175 |
Short Term Investments | 110.986 | 206.477 | 55.969 | 100.209 | 239.106 |
Total Receivables, Net | 2.826 | 2.74 | 3.992 | 11.557 | 5.538 |
Accounts Receivable - Trade, Net | 0.001 | 0 | 0.015 | 0.063 | 0.159 |
Total Inventory | |||||
Prepaid Expenses | 2.784 | 2.01 | 4.932 | 6.745 | 19.82 |
Total Assets | 234.197 | 335.825 | 191.462 | 293.462 | 419.352 |
Property/Plant/Equipment, Total - Net | 14.841 | 13.597 | 16.211 | 23.283 | 10.828 |
Property/Plant/Equipment, Total - Gross | 33.143 | 21.356 | 28.658 | 38.416 | 106.498 |
Accumulated Depreciation, Total | -18.302 | -7.76 | -12.447 | -15.133 | -95.67 |
Goodwill, Net | |||||
Intangibles, Net | 96.312 | 96.312 | 96.32 | 96.341 | 96.885 |
Other Long Term Assets, Total | -0.001 | -0.001 | |||
Total Current Liabilities | 28.009 | 41.716 | 34.67 | 54.974 | 96.983 |
Accounts Payable | 3.763 | 10.338 | 6.808 | 12.303 | 16.335 |
Accrued Expenses | 8.11 | 29.171 | 25.414 | 30.016 | 50.64 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 14.023 | 1.153 | 0.848 | 5.926 | 30.008 |
Total Liabilities | 41.408 | 54.679 | 49.557 | 109.006 | 111.746 |
Total Long Term Debt | 13.399 | 12.964 | 14.888 | 37.153 | 0 |
Deferred Income Tax | 0 | ||||
Total Equity | 192.789 | 281.146 | 141.905 | 184.456 | 307.606 |
Common Stock | 27.868 | 27.868 | 188.494 | 188.494 | 188.494 |
Additional Paid-In Capital | 805.349 | 804.944 | 420.804 | 420.208 | 420.208 |
Retained Earnings (Accumulated Deficit) | -637.184 | -548.419 | -463.655 | -421.035 | -297.595 |
Other Equity, Total | -3.244 | -3.247 | -3.738 | -3.211 | -3.501 |
Total Liabilities & Shareholders’ Equity | 234.197 | 335.825 | 191.462 | 293.462 | 419.352 |
Total Common Shares Outstanding | 55.7242 | 55.7242 | 29.5796 | 29.5796 | 29.5797 |
Other Current Assets, Total | 0.001 | ||||
Other Liabilities, Total | -0.001 | -0.001 | 16.879 | 14.763 | |
Note Receivable - Long Term | 0 | 0 | 21.027 | ||
Current Port. of LT Debt/Capital Leases | 2.113 | 1.054 | 1.6 | 6.729 | |
Capital Lease Obligations | 13.399 | 12.964 | 14.888 | 37.153 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total Current Assets | 89.8 | 105.7 | 123.044 | 147.5 | 168.2 |
Cash and Short Term Investments | 82.8 | 100.8 | 117.434 | 142.2 | 162.8 |
Cash | 6.3 | 4.9 | 6.448 | 7 | 4.6 |
Short Term Investments | 76.5 | 95.9 | 110.986 | 135.2 | 158.2 |
Total Receivables, Net | 7 | 4.9 | 2.826 | 5.3 | 5.4 |
Accounts Receivable - Trade, Net | 7 | 4.9 | 0.001 | 5.3 | 5.4 |
Total Assets | 199.8 | 216.2 | 234.197 | 259.3 | 276.9 |
Property/Plant/Equipment, Total - Net | 13.7 | 14.1 | 14.841 | 15.5 | 12.4 |
Intangibles, Net | 96.3 | 96.3 | 96.312 | 96.3 | 96.3 |
Note Receivable - Long Term | |||||
Other Long Term Assets, Total | 0.1 | ||||
Total Current Liabilities | 39.4 | 29.4 | 28.009 | 33.9 | 39.5 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 39.4 | 29.4 | 1.46 | 33.9 | 39.5 |
Total Liabilities | 51.9 | 42.3 | 41.408 | 48.8 | 51.6 |
Total Long Term Debt | 12.5 | 12.8 | 13.399 | 14.9 | 12.1 |
Capital Lease Obligations | 12.5 | 12.8 | 13.399 | 14.9 | 12.1 |
Total Equity | 147.9 | 173.9 | 192.789 | 210.5 | 225.3 |
Common Stock | 28.4 | 27.9 | 27.868 | 27.9 | 27.9 |
Additional Paid-In Capital | 805.6 | 805.3 | 805.349 | 804.9 | 804.9 |
Retained Earnings (Accumulated Deficit) | -682.9 | -656.1 | -637.184 | -619.1 | -604.3 |
Other Equity, Total | -3.2 | -3.2 | -3.244 | -3.2 | -3.2 |
Total Liabilities & Shareholders’ Equity | 199.8 | 216.2 | 234.197 | 259.3 | 276.9 |
Total Common Shares Outstanding | 54.976 | 55.7246 | 55.7242 | 55.7246 | 55.7246 |
Prepaid Expenses | 2.784 | ||||
Other Liabilities, Total | 0.1 | ||||
Accounts Payable | 3.763 | ||||
Accrued Expenses | 20.673 | ||||
Current Port. of LT Debt/Capital Leases | 2.113 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -88.765 | -62.579 | -42.62 | -123.334 | -350.475 |
Cash From Operating Activities | -101.82 | -48.734 | -58.053 | -148.255 | -318.63 |
Cash From Operating Activities | 2.571 | 2.595 | 4.43 | 7.086 | 26.304 |
Non-Cash Items | 0 | -16.968 | -18.293 | 30.583 | |
Cash Taxes Paid | 0 | 1.214 | -0.799 | -1.946 | -2.987 |
Cash Interest Paid | 1.315 | 0.015 | |||
Changes in Working Capital | -15.626 | 11.25 | -2.895 | -13.714 | -25.042 |
Cash From Investing Activities | -0.382 | 0 | 5.368 | 4.49 | -6.838 |
Capital Expenditures | -0.382 | 0 | -2.684 | -1.436 | -6.838 |
Other Investing Cash Flow Items, Total | 0 | 8.052 | 5.926 | ||
Cash From Financing Activities | -1.535 | 199.4 | -12.118 | -6.659 | 143.79 |
Financing Cash Flow Items | 0.001 | -24.115 | -12.713 | -6.659 | -11.287 |
Issuance (Retirement) of Stock, Net | 0.404 | 223.515 | 0.595 | 0 | 155.077 |
Foreign Exchange Effects | 0.003 | 0.494 | 0.301 | -1.349 | 0.18 |
Net Change in Cash | -103.734 | 151.16 | -64.502 | -151.773 | -181.498 |
Issuance (Retirement) of Debt, Net | -1.94 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Cash From Operating Activities | -16.1 | -101.82 | -77.1 | -57.5 | -39.9 |
Changes in Working Capital | -16.1 | -101.82 | -77.1 | -57.5 | -39.9 |
Cash From Investing Activities | 0 | -0.382 | -0.4 | 0 | 0 |
Other Investing Cash Flow Items, Total | |||||
Cash From Financing Activities | -0.5 | -1.535 | -1.4 | -1 | -0.5 |
Financing Cash Flow Items | -0.5 | 0.001 | -1.4 | -1 | -0.5 |
Issuance (Retirement) of Stock, Net | 0 | 0.404 | 0 | 0 | |
Foreign Exchange Effects | 0 | 0.003 | 0 | 0 | 0 |
Net Change in Cash | -16.6 | -103.734 | -78.9 | -58.5 | -40.4 |
Capital Expenditures | 0 | -0.382 | -0.4 | 0 | 0 |
Issuance (Retirement) of Debt, Net | -1.94 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Medivir Company profile
About Medivir AB
Medivir AB is a Sweden-based pharmaceutical research and development company with focus on oncology. The Company specializes in protease inhibitor design and nucleoside and nucleotide science, applying it to development of therapies for cancers with unmet medical need. The Company's clinical pipeline consists of remetinostat, a topical histone deacetylase (HDAC) inhibitor in phase II of clinical studies for the treatment of cutaneous T-cell lymphoma (CTCL), birinapant in combination with Keytruda (pembrolizumab) in phase I of clinical studies for the treatment of solid tumors, MIV-818, a nucleotide-based prodrug in phase I of clinical trials for the treatment of liver cancer, and MIV-711, a cathepsin K (CTSK) inhibitor in IIa extension study for the treatment of osteoarthritis. Furthermore, the Company has additional research projects in cooperation with other institutions.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Medivir AB revenues increased 83% to SEK25.5M. Net loss increased 48% to SEK63.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -SEK1.44 to -SEK1.19.
Equity composition
01/2007, Rigths Issue, 3 new shares for every 5 shares held @ SEK 29 (Factor: 1.224545). 04/2010, Rights Issue, 1 new share for every 4 shares held @ SEK 62 (Factor: 1.10266). 2/2015, complex stock split (Factor: 1.59182) 1/2021, Rights Issue, 1 new share for every 1 share held @ SEK7 (Factor: 1.21788).
Industry: | Bio Therapeutic Drugs |
Lunastigen 5, 2 tr
HUDDINGE
STOCKHOLM 141 22
SE
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com